180 Life Sciences EBITDA

Cos'è EBITDA di 180 Life Sciences?

EBITDA di 180 Life Sciences Corp. è -$16.63

Qual è la definizione di EBITDA?



L'EBITDA è il reddito di una società prima di interessi, imposte, deprezzamenti e ammortamenti ed è una misura contabile calcolata utilizzando gli utili netti di una società, prima che vengano sottratti interessi passivi, imposte, ammortamenti e ammortamenti come proxy della redditività corrente di un'azienda.

Although EBITDA is not a financial measure recognized in generally accepted accounting principles, it is widely used in many areas of finance when assessing the performance of a company, such as securities analysis. It is intended to allow a comparison of profitability between different companies, by discounting the effects of interest payments from different forms of financing (by ignoring interest payments), political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill). EBITDA is a financial measurement of cash flow from operations that is widely used in mergers and acquisitions of small businesses and businesses in the middle market. It is not unusual for adjustments to be made to EBITDA to normalize the measurement allowing buyers to compare the performance of one business to another.

EBITDA di aziende nel Health Care settore su NASDAQ rispetto a 180 Life Sciences

Cosa fa 180 Life Sciences?

180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of novel drugs for unmet medical needs in chronic pain, inflammation, inflammatory diseases, and fibrosis. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and anti-tumour necrosis factor (Anti-TNF) platform, which focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.

Aziende con ebitda simili a 180 Life Sciences